腺苷A1R/A3R激动剂AST-004在健康受试者中的首次人体I期临床试验
AST-004是一种小分子腺苷A1/A3受体激动剂,在急性缺血性卒中和创伤性脑损伤临床前模型中显示出显著脑保护作用。本I期首次人体研究在健康受试者中评估单次递增静脉剂量的安全性和耐受性,并表征血浆、脑脊液和尿液中的单剂量药代动力学特征。结果显示AST-004安全且耐受良好,脑脊液浓度在60分钟采集时间点最高。
要点
- AST-004在健康受试者中单次递增静脉给药安全且耐受良好,未观察到严重或重度不良事件。
- 42例受试者接受AST-004,其中12例出现治疗中出现的不良事件,最常见为头痛。
- 药代动力学分析证实AST-004分布至脑脊液,脑脊液与血浆比值在3个采样时间点内升高。
核心结论
- AST-004在血浆浓度较星形胶质细胞临床前灵长类卒中疗效研究中与显著疗效相关的浓度高3至8倍时安全且耐受良好,脑脊液浓度在60分钟采集时间点(最后一个测试时间点)最高。
- 本研究支持额外的临床研究,包括评估延长输注以支持卒中和创伤性脑损伤的2期项目。
研究设计与样本
- 本研究为I期首次人体临床试验,在健康受试者中评估单次递增静脉给药的安全性和耐受性(主要目标)以及血浆、脑脊液和尿液中的单剂量药代动力学特征(次要目标)。
- 第1部分中,AST-004按5、25、50、75和100 mg递增剂量队列给药,每个队列6例受试者接受研究药物,2例接受安慰剂。
- 第2部分中,全部12例受试者接受100 mg静脉输注研究药物,随后每例受试者在输注后20、40或60分钟通过腰椎穿刺进行单次脑脊液采集。
主要发现
- 共有42例受试者接受AST-004,未观察到严重或重度不良事件。
- 12例受试者出现治疗中出现的不良事件,各组中最常见的是头痛。
- 第2部分中,药代动力学分析证实AST-004分布至脑脊液,脑脊液与血浆比值在采样的3个时间点内升高。
- 25至100 mg剂量的平均半衰期为1.1至1.4小时,最高给药队列(100 mg)获得的几何平均最大血浆浓度为2232±428 ng/mL。
局限性
- 本研究支持额外的临床研究,包括评估延长输注以支持卒中和创伤性脑损伤的2期项目。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: AST-004 is a small-molecule adenosine A1/A3 receptor agonist that has exhibited significant cerebroprotective efficacy in preclinical models of acute ischemic stroke and traumatic brain injury. The primary objectives of this clinical phase I first-in-human study were to evaluate the safety and tolerability profile of single ascending intravenous doses in healthy subjects. The secondary objectives were to characterize the single-dose pharmacokinetic profiles in plasma, cerebrospinal fluid (CSF), and urine. METHODS: In part 1 of the study, AST-004 was administered in ascending dose cohorts of 5, 25, 50, 75, and 100 mg, with 6 subjects in each cohort receiving the study drug and 2 receiving placebo. In part 2, all 12 subjects received a 100 mg IV infusion of the study drug followed by a single CSF collection per subject via lumbar puncture at 20, 40, or 60 minutes after infusion. RESULTS: A total of 42 subjects received AST-004, with no severe or serious adverse events observed. Twelve of these subjects experienced a treatment-emergent adverse event, the most frequent across groups being headache. In part 2, pharmacokinetic analyses confirmed that AST-004 was distributed in the CSF, with the CSF-to-plasma ratio increasing over the 3 timepoints sampled. The mean half-life was 1.1 to 1.4 hours for doses of 25 to 100 mg, and the geometric mean maximum plasma concentration obtained in the highest dosing cohort (100 mg) was 2232±428 ng/mL. CONCLUSIONS: AST-004 was safe and well-tolerated at plasma concentrations 3 to 8× higher than those associated with significant efficacy in astrocyte's preclinical primate stroke efficacy studies, with CSF concentrations highest at the 60-minute collection timepoint, the last timepoint tested. This study supports additional clinical investigations, including evaluation of an extended infusion to support the phase 2 program in stroke and traumatic brain injury.
引用
- Manna LM, Hernandez J, Hunt DE, et al. First-in-Human Phase I Clinical Trial of the Adenosine A1R/A3R Agonist AST-004 in Healthy Subjects. Stroke. 2024. PMID: 39450498. doi:10.1161/STROKEAHA.124.047207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。